Global Palonosetron Hydrochloride Injection Market Growth 2025-2031
Description
The global Palonosetron Hydrochloride Injection market size is predicted to grow from US$ 153 million in 2025 to US$ 179 million in 2031; it is expected to grow at a CAGR of 2.7% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Palonosetron hydrochloride injection is a second-generation 5‑HT₃ receptor antagonist with high receptor affinity, indicated for prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV), and postoperative nausea and vomiting (PONV) within 24 hours of surgery. It is supplied as a sterile, clear, buffered IV solution in 5 mL (0.25 mg) and 1.5 mL (0.075 mg) vials, with a pH of approximately 4.5–5.5. The adult dose for CINV prophylaxis is 0.25 mg IV over 30 seconds, administered approximately 30 minutes before chemotherapy; for PONV prevention, a 0.075 mg IV dose is given immediately before anesthesia induction. Pediatric dosing is 20 μg/kg (up to 1.5 mg), infused over 15 minutes before chemotherapy. Common adverse events include headache and constipation; rare but notable effects include QT prolongation, arrhythmias, injection site reactions, and hypersensitivity including anaphylaxis. With its long elimination half-life (~40–50 hours) and efficacy against both immediate and delayed vomiting, palonosetron stands out among 5‑HT₃ antagonists.
Currently, palonosetron hydrochloride injection has become the preferred antiemetic agent in many clinical settings for chemotherapy-induced nausea and vomiting (CINV), especially among patients undergoing repeated and multi-cycle chemotherapy. Compared to first-generation 5-HT₃ receptor antagonists, it demonstrates longer-lasting and more stable efficacy, particularly in controlling delayed-phase nausea. Its use has been widely adopted across oncology and anesthesiology departments in developed markets such as the U.S., Europe, and Japan. In recent years, its application in the prevention of postoperative nausea and vomiting (PONV) has also expanded due to rising standards in perioperative care. Some developing countries have gradually begun to include palonosetron in treatment guidelines and reimbursement schemes, improving global market penetration.
Looking ahead, the rising global cancer incidence, increasing combination of cytotoxic and targeted therapies, and the growing emphasis on patient quality of life are expected to drive continued demand for palonosetron injection. With its long half-life, minimal side effects, and convenience of single-dose administration covering multiple emesis phases, it is being increasingly adopted in first-line antiemetic regimens. Its role is particularly significant in regimens involving highly emetogenic agents such as platinum compounds. Future innovation in formulations—such as multi-dose vials, extended-release injections, or fixed-dose combinations—may further enhance its versatility and market potential.
Despite the strong outlook, several challenges remain. Initially, patent protections restricted the availability of generic alternatives, and although some markets have since opened, the drug remains expensive with limited reimbursement in certain regions. In parts of Asia and other developing areas, prescribing preferences still lean toward traditional agents like ondansetron. Additionally, the emergence of NK-1 receptor antagonists and combination antiemetic regimens presents competitive pressure, potentially affecting palonosetron's market share if positioning strategies are not adapted.
LP Information, Inc. (LPI) ' newest research report, the “Palonosetron Hydrochloride Injection Industry Forecast” looks at past sales and reviews total world Palonosetron Hydrochloride Injection sales in 2024, providing a comprehensive analysis by region and market sector of projected Palonosetron Hydrochloride Injection sales for 2025 through 2031. With Palonosetron Hydrochloride Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Palonosetron Hydrochloride Injection industry.
This Insight Report provides a comprehensive analysis of the global Palonosetron Hydrochloride Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Palonosetron Hydrochloride Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Palonosetron Hydrochloride Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Palonosetron Hydrochloride Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Palonosetron Hydrochloride Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Palonosetron Hydrochloride Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
1.5ml
5ml
Segmentation by Application:
Hospital
Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Otsuka Pharmaceutical
Helsinn
Fresenius
Dr Reddy's Laboratories
Juniper Biologics
Intas Pharmaceuticals
Sichuan Kelun Pharmaceutical
Jiangsu Aosaikang Pharmaceutical
Yangtze River Pharmaceutical
Qilu Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Hangzhou Jiuyuan Genetic
Key Questions Addressed in this Report
What is the 10-year outlook for the global Palonosetron Hydrochloride Injection market?
What factors are driving Palonosetron Hydrochloride Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Palonosetron Hydrochloride Injection market opportunities vary by end market size?
How does Palonosetron Hydrochloride Injection break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Palonosetron hydrochloride injection is a second-generation 5‑HT₃ receptor antagonist with high receptor affinity, indicated for prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV), and postoperative nausea and vomiting (PONV) within 24 hours of surgery. It is supplied as a sterile, clear, buffered IV solution in 5 mL (0.25 mg) and 1.5 mL (0.075 mg) vials, with a pH of approximately 4.5–5.5. The adult dose for CINV prophylaxis is 0.25 mg IV over 30 seconds, administered approximately 30 minutes before chemotherapy; for PONV prevention, a 0.075 mg IV dose is given immediately before anesthesia induction. Pediatric dosing is 20 μg/kg (up to 1.5 mg), infused over 15 minutes before chemotherapy. Common adverse events include headache and constipation; rare but notable effects include QT prolongation, arrhythmias, injection site reactions, and hypersensitivity including anaphylaxis. With its long elimination half-life (~40–50 hours) and efficacy against both immediate and delayed vomiting, palonosetron stands out among 5‑HT₃ antagonists.
Currently, palonosetron hydrochloride injection has become the preferred antiemetic agent in many clinical settings for chemotherapy-induced nausea and vomiting (CINV), especially among patients undergoing repeated and multi-cycle chemotherapy. Compared to first-generation 5-HT₃ receptor antagonists, it demonstrates longer-lasting and more stable efficacy, particularly in controlling delayed-phase nausea. Its use has been widely adopted across oncology and anesthesiology departments in developed markets such as the U.S., Europe, and Japan. In recent years, its application in the prevention of postoperative nausea and vomiting (PONV) has also expanded due to rising standards in perioperative care. Some developing countries have gradually begun to include palonosetron in treatment guidelines and reimbursement schemes, improving global market penetration.
Looking ahead, the rising global cancer incidence, increasing combination of cytotoxic and targeted therapies, and the growing emphasis on patient quality of life are expected to drive continued demand for palonosetron injection. With its long half-life, minimal side effects, and convenience of single-dose administration covering multiple emesis phases, it is being increasingly adopted in first-line antiemetic regimens. Its role is particularly significant in regimens involving highly emetogenic agents such as platinum compounds. Future innovation in formulations—such as multi-dose vials, extended-release injections, or fixed-dose combinations—may further enhance its versatility and market potential.
Despite the strong outlook, several challenges remain. Initially, patent protections restricted the availability of generic alternatives, and although some markets have since opened, the drug remains expensive with limited reimbursement in certain regions. In parts of Asia and other developing areas, prescribing preferences still lean toward traditional agents like ondansetron. Additionally, the emergence of NK-1 receptor antagonists and combination antiemetic regimens presents competitive pressure, potentially affecting palonosetron's market share if positioning strategies are not adapted.
LP Information, Inc. (LPI) ' newest research report, the “Palonosetron Hydrochloride Injection Industry Forecast” looks at past sales and reviews total world Palonosetron Hydrochloride Injection sales in 2024, providing a comprehensive analysis by region and market sector of projected Palonosetron Hydrochloride Injection sales for 2025 through 2031. With Palonosetron Hydrochloride Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Palonosetron Hydrochloride Injection industry.
This Insight Report provides a comprehensive analysis of the global Palonosetron Hydrochloride Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Palonosetron Hydrochloride Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Palonosetron Hydrochloride Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Palonosetron Hydrochloride Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Palonosetron Hydrochloride Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Palonosetron Hydrochloride Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
1.5ml
5ml
Segmentation by Application:
Hospital
Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Otsuka Pharmaceutical
Helsinn
Fresenius
Dr Reddy's Laboratories
Juniper Biologics
Intas Pharmaceuticals
Sichuan Kelun Pharmaceutical
Jiangsu Aosaikang Pharmaceutical
Yangtze River Pharmaceutical
Qilu Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Hangzhou Jiuyuan Genetic
Key Questions Addressed in this Report
What is the 10-year outlook for the global Palonosetron Hydrochloride Injection market?
What factors are driving Palonosetron Hydrochloride Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Palonosetron Hydrochloride Injection market opportunities vary by end market size?
How does Palonosetron Hydrochloride Injection break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
114 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Palonosetron Hydrochloride Injection by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Palonosetron Hydrochloride Injection by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
